AAMS Infectious Diseases & Microbiology · Vol. 1 · Issue 3 · 2024-09-20
Novel mRNA Vaccine Platform Against Emerging Coronaviruses: Preclinical Evaluation
Becker F, Schneider T, Richter L
Institute of Virology, Charité – Universitätsmedizin Berlin, Berlin, Germany¹; BioNTech Research, Mainz, Germany²
Abstract
Development and preclinical evaluation of a pan-coronavirus mRNA vaccine targeting conserved spike protein epitopes, demonstrating broad neutralizing antibody responses against SARS-CoV-2 variants and related coronaviruses.
Keywords: mRNA Vaccine, Coronavirus, Preclinical Study, Neutralizing Antibodies, Pan-Coronavirus
Full Text
Development and preclinical evaluation of a pan-coronavirus mRNA vaccine targeting conserved spike protein epitopes, demonstrating broad neutralizing antibody responses against SARS-CoV-2 variants and related coronaviruses.
This article is published open access by AAMS Infectious Diseases & Microbiology. The complete peer-reviewed text can be read on the journal page.
Author Citation Metrics
Metrics are sourced from public bibliometric records (OpenAlex) and each author's Google Scholar profile.